CRISPR/Cas9 Licensing Agreement Means New Opportunities for Öresund-based Companies

CRISPR/Cas9 Licensing Agreement Means New Opportunities for Öresund-based Companies

Bioneer A/S and ERS Genomics Limited announced recently a non-exclusive license agreement to provide Bioneer with access to ERS Genomic’s CRISPR/Cas9 genome editing technology patents.

Bioneer will with the CRISPR/Cas9 license, strengthen the state-of-the-art gene editing core facility and capability to generate innovative, custom-designed cell lines.

Read more about the news on Bioneer's homepage here

Bioneer A/S